标签归档：vistamycin

Ribostamycin (Synonyms: Vistamycin; SF-733)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Ribostamycin  (Synonyms: Vistamycin; SF-733)

Ribostamycin (Vistamycin) 是一种广谱氨基糖苷类抗生素 (antibiotic)。Ribostamycin 对革兰氏阴性和革兰氏阳性细菌感染有效。Ribostamycin 还抑制 PDI 的伴侣活性。

Ribostamycin (Synonyms: Vistamycin; SF-733)

Ribostamycin Chemical Structure

CAS No. : 25546-65-0

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Ribostamycin 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

Ribostamycin (Vistamycin) is a broad-spectrum aminoglycoside antibiotic. Ribostamycin is effective against Gram-Negative and Gram-Positive bacterial infection. Ribostamycin also inhibits the chaperone activity of PDI[1][2].

IC50 & Target

Aminoglycoside

 

体外研究
(In Vitro)

Ribostamycin 抑制 Borrelia burgdorferi 活性，MIC90 为 32 mg/L[2]。
Ribostamycin (1-100 μM, 0-15 min) 可抑制 PDI 的分子伴侣活性[3]。
Ribostamycin 抑制大肠杆菌 (Escherichia coli) 活性，MIC 为 0.9-7.2 μM[4]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Ribostamycin 相关抗体:

Cell Viability Assay[4]

Cell Line: Escherichia coli strains
Concentration: 0-64 μg/mL
Incubation Time: 14 h
Result: Inhibited Escherichia coli strains with a MIC of 0.9-7.2 μM.

体内研究
(In Vivo)

Ribostamycin (40 mg/kg，肌肉注射，每天，持续 14 天) 对大鼠几乎没有肾毒性 (通过尿液分析评估)[5]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

454.47

Formula

C17H34N4O10
CAS 号

25546-65-0
结构分类
  • Antibiotics
  • Disease Research
  • Antibacterial
  • Antibiotics
  • Other Antibiotics
初始来源
  • 微生物

Streptomyces ribosidificus
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (536 KB) 产品使用指南 (1538 KB)

参考文献

  • [1]. Zheng T, et al. Linear self-assembly formation between gold nanoparticles and aminoglycoside antibiotics. Colloids Surf B Biointerfaces. 2018 Apr 1;164:185-191.  [Content Brief]

    [2]. Hunfeld KP, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001 Mar;17(3):203-8.  [Content Brief]

    [3]. Horibe T, et al. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72.  [Content Brief]

    [4]. Kong J, et al. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol. 2020 Jul 29;11:1718.  [Content Brief]

    [5]. Kitasato I, et al. Comparative nephrotoxicity of ribostamycin and gentamicin in rats evaluated by urinalysis. Drugs Exp Clin Res. 1989;15(6-7):273-89.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务